Prenetics (PRE) Q1 2026: IM8 Revenue Surges 6x, Subscription Model Drives 64% Gross Margins
Prenetics delivered a transformative Q1, with IM8 revenue scaling nearly sixfold and margin expansion signaling a new business era. The company’s pivot to a global, recurring subscription model is compounding customer lifetime value and driving rapid cash flow improvements. With new product launches and channel diversification ahead, PRE’s trajectory points to further upside beyond raised guidance.
Summary
- Subscription Model Reshapes Economics: Quarterly subscriptions and global rollout compress payback and boost retention.
- Margin Expansion Accelerates: Scale, product mix, and operational discipline drive significant gross margin gains.
- Product Pipeline and Channel Upside Set Stage: New SKUs and marketing diversification not yet reflected in guidance.
Business Overview
Prenetics is a consumer health company focused on science-backed supplements and wellness products, generating revenue primarily through its IM8 brand. The business operates a direct-to-consumer (DTC) subscription model, selling recurring health supplement subscriptions to a global customer base spanning 43 countries. The IM8 segment now accounts for the vast majority of revenue, with legacy diagnostics and genomics units divested to concentrate capital and execution on the high-growth core.
Performance Analysis
Prenetics delivered a step-change in performance, with total revenue reaching $36 million, up over 330% year-over-year. IM8, the flagship supplement subscription brand, contributed $33.8 million, representing nearly 6x YoY growth and over 93% of segment revenue. Gross margin at the IM8 segment expanded to 64%, a 400 basis point sequential improvement, driven by manufacturing scale, improved supplier terms, a shift to higher-margin SKUs, and fulfillment efficiencies.
Active subscribers grew to 82,000, with 93% of IM8 revenue now recurring, underscoring the success of the shift to quarterly subscriptions. Notably, average order value (AOV) jumped from $157 in Q4 2025 to $240 in Q1 2026, a 53% sequential increase. This transition compresses payback periods and accelerates cash flow, while cohort data shows rapid gains in customer lifetime value (LTV): the January 2026 cohort generated $587 per customer in four months, compared to $549 over twelve months for the January 2025 cohort.
- Servings Delivered Outpace Orders: 8.8 million servings delivered, up 28% sequentially, as quarterly subscriptions increase volume per order.
- Marketing Investment Scales: $22 million spent in Q1 to support global subscription rollout and creative expansion.
- Adjusted EBITDA Loss Remains Disciplined: Despite rapid growth, EBITDA losses held steady as scale and margin gains offset marketing outlays.
Momentum continued into April and May, with monthly IM8 revenue tracking toward $186 million annualized, setting up for continued sequential acceleration into Q2 and beyond.
Executive Commentary
"The Prenetics you see today is something entirely different. We are now a care play consumer health company anchored by IM8. Recurring subscription revenue, expanding gross margins, global distribution across 43 countries, operating disciplines built around unit economics."
Danny Young, Chief Executive Officer and Co-Founder
"In my career, I've looked at hundreds of cohort curves on supplement brands, but I've never seen LTV numbers like this. 81% repeat revenue, $240 new customer AOV, 2026 cohorts that are tracking to 900 to 1,100 in 12-month revenue per customer. This isn't a marketing story. It's what disciplined unit economics looks like when a brand hits product market fit at scale."
Brian Rosen, Chief Financial Officer of IM8
Strategic Positioning
1. Subscription Model as Core Growth Engine
Quarterly subscriptions are now the backbone of the business, with 79% of new customers opting in and AOV climbing sharply. This model compresses payback, boosts retention, and accelerates LTV, creating a compounding effect on both revenue and cash flow. The company’s transition from one-off orders to high-frequency, high-value recurring revenue is a structural shift that underpins improved financial predictability and operating leverage.
2. Global Athlete Equity Alignment
Prenetics has built a unique athlete equity partnership model, aligning the incentives of global sports icons—such as David Beckham, Irina Sabalenka, and Giannis Antetokounmpo—with the company’s long-term brand and product success. These relationships are not traditional sponsorships but equity-based partnerships, resulting in authentic advocacy at a fraction of the cost of typical celebrity deals. The recent InterMiami partnership, featuring Lionel Messi, further cements brand credibility and provides a durable moat in credibility-driven categories.
3. AI-Driven Marketing and Channel Diversification
Prenetics’ AI-powered creative engine now deploys over 3,000 live Meta ads and 600 new creatives weekly, enabling rapid testing and iteration. The company is actively reducing dependence on Meta, expanding into TikTok, YouTube, and Applovin, with early results from TikTok affiliate campaigns and direct discussions with platform leadership. This data-driven approach is expected to unlock new audiences and improve acquisition efficiency, with channel mix projected to shift from 85% Meta to 55% by year-end.
4. Product Pipeline and Upside Optionality
Three new products—hydration, creatine, and kids’ gummies—are set to launch in Q4 2026, targeting large, fast-growing categories and leveraging existing subscriber trust. These launches are expected to drive $178 to $378 in incremental second-year revenue per customer, with all upside excluded from current guidance. Each SKU leverages core brand strengths: clinical validation, athlete endorsement, and household cross-sell potential.
5. Capital Allocation and Balance Sheet Strength
With $147 million in financial assets and no debt, Prenetics has ample firepower to fund growth. The company exited its Bitcoin position for $41.3 million in cash, with proceeds earmarked for share repurchases, marketing, product launches, and international expansion. Management’s personal open-market purchases reinforce alignment and conviction.
Key Considerations
This quarter marked a decisive pivot for Prenetics, with the company demonstrating not only rapid top-line growth but fundamental improvements in margin structure, retention, and capital efficiency. The raised guidance and cohort data suggest the core engine is still accelerating, while new product and channel levers remain untapped in the current forecast.
Key Considerations:
- Payback Compression: Quarterly subscriptions and higher AOV are shrinking payback periods, improving working capital and cash conversion.
- Cohort Quality Surpasses Peers: 81% repeat revenue and LTV tracking above $900 per customer position IM8 ahead of public DTC competitors.
- Marketing Efficiency in Flux: AI-driven creative and channel diversification offer acquisition upside but require ongoing execution to sustain efficiency as scale increases.
- Product Launches as Catalysts: Hydration, creatine, and kids’ gummies target large, underpenetrated markets and are expected to drive cross-sell and LTV expansion.
- Balance Sheet Optionality: Strong liquidity and recent Bitcoin exit provide flexibility for opportunistic investment and shareholder returns.
Risks
Execution risk remains high as Prenetics scales globally and diversifies channels, especially with rapid marketing investment and new product launches. Channel concentration, while improving, exposes the company to platform policy shifts and CPM volatility. Regulatory scrutiny of supplement claims and the need for ongoing clinical validation could introduce compliance or reputational risks. Finally, competitive intensity in global supplements and potential dilution of athlete partnerships warrant close monitoring as the business grows.
Forward Outlook
For Q2 2026, Prenetics guided to:
- Total revenue of $46 million to $48 million
- IM8 revenue of $44 million to $46 million (implying 33% sequential growth)
For full-year 2026, management raised guidance:
- IM8 revenue of $190 million to $210 million (up from $180 million to $200 million)
Management highlighted several factors that frame the outlook:
- None of the Q4 product launches are included in guidance, presenting incremental upside.
- New marketing channels (TikTok, YouTube, Applovin) are in early ramp, with success not yet quantified in forecasts.
Takeaways
Prenetics’ Q1 results mark a strategic inflection as the company transitions from legacy diagnostics to a high-growth, subscription-based consumer health platform, with strong cohort economics and operational discipline underpinning the story.
- Recurring Revenue Engine: Subscription adoption and global reach are compounding customer economics and accelerating growth.
- Margin and LTV Expansion: Scale, product mix, and retention improvements are delivering durable margin expansion and best-in-class cohort quality.
- Future Watchpoints: Execution in new channels, successful multi-SKU launches, and sustained marketing efficiency will be pivotal for further upside.
Conclusion
Prenetics has redefined its business model and delivered a quarter of exceptional growth, margin expansion, and operational discipline. With a strong capital base and multiple growth levers yet to be realized in guidance, the company is positioned as a top-tier emerging consumer health platform with significant upside potential.
Industry Read-Through
Prenetics’ results highlight a broader shift in the supplements and consumer health sector toward subscription-driven, science-backed, and influencer-aligned models. The rapid adoption of quarterly subscriptions, AI-powered marketing, and authentic athlete partnerships set a new standard for customer retention and LTV in DTC health. For peers, the bar for clinical validation and capital-efficient growth is rising, while channel diversification and creative agility are becoming prerequisites for sustained scale. The sector is likely to see increased competitive pressure on legacy brands as digital-first challengers build global, recurring revenue engines with superior economics and brand equity.